HC Wainwright Issues Positive Forecast for SGMO Earnings

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) – Stock analysts at HC Wainwright lifted their Q3 2025 EPS estimates for Sangamo Therapeutics in a report released on Wednesday, May 14th. HC Wainwright analyst P. Trucchio now expects that the biopharmaceutical company will post earnings per share of ($0.08) for the quarter, up from their previous forecast of ($0.11). HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Sangamo Therapeutics’ current full-year earnings is ($0.46) per share. HC Wainwright also issued estimates for Sangamo Therapeutics’ FY2025 earnings at ($0.17) EPS, FY2026 earnings at ($0.17) EPS and FY2027 earnings at ($0.04) EPS.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its quarterly earnings data on Monday, May 12th. The biopharmaceutical company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.03). Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%. The firm had revenue of $6.44 million for the quarter, compared to analysts’ expectations of $7.90 million.

SGMO has been the subject of a number of other reports. Royal Bank of Canada restated a “sector perform” rating and issued a $2.00 price objective on shares of Sangamo Therapeutics in a report on Tuesday, March 18th. Barclays lowered their price objective on shares of Sangamo Therapeutics from $9.00 to $5.00 and set an “overweight” rating for the company in a report on Wednesday, May 14th. Finally, Truist Financial lowered their price objective on shares of Sangamo Therapeutics from $7.00 to $5.00 and set a “buy” rating for the company in a report on Thursday, January 23rd. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, Sangamo Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $4.50.

Sangamo Therapeutics Stock Performance

Shares of SGMO opened at $0.50 on Monday. The firm has a market cap of $116.23 million, a price-to-earnings ratio of -0.66 and a beta of 1.46. Sangamo Therapeutics has a fifty-two week low of $0.30 and a fifty-two week high of $3.18. The firm has a 50 day moving average price of $0.72 and a 200-day moving average price of $1.30.

Institutional Investors Weigh In On Sangamo Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Jacobs Levy Equity Management Inc. raised its holdings in Sangamo Therapeutics by 74.8% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 1,297,785 shares of the biopharmaceutical company’s stock valued at $851,000 after buying an additional 555,323 shares during the last quarter. Caption Management LLC bought a new stake in Sangamo Therapeutics during the 1st quarter valued at $37,000. OMERS ADMINISTRATION Corp raised its holdings in Sangamo Therapeutics by 93.7% during the 1st quarter. OMERS ADMINISTRATION Corp now owns 207,800 shares of the biopharmaceutical company’s stock valued at $136,000 after buying an additional 100,500 shares during the last quarter. Invesco Ltd. raised its holdings in Sangamo Therapeutics by 82.8% during the 1st quarter. Invesco Ltd. now owns 483,894 shares of the biopharmaceutical company’s stock valued at $317,000 after buying an additional 219,253 shares during the last quarter. Finally, GSA Capital Partners LLP raised its holdings in Sangamo Therapeutics by 2,962.2% in the 1st quarter. GSA Capital Partners LLP now owns 966,202 shares of the biopharmaceutical company’s stock worth $634,000 after purchasing an additional 934,649 shares in the last quarter. 56.93% of the stock is currently owned by institutional investors.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.